Nanjing-based GenScript Biotech Corporation shared its progress in the cell and gene therapy industry on the sideline of the J.P. Morgan 38th Annual Healthcare Conference (JPM 2020) held in San Francisco from January 13 to 16.

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and investors.

The participants showed a lot of interest in GenScript. Speakers further discussed hot topics such as how to reduce the side effects of treatment, improve the treatment, and expand the scale of production in the industry. Among other focuses, the advantages of the Chinese market and China's requirements for the scale of capital to achieve scale production are of the greatest concern.

"At present, the landscape of the world's innovative drug R&D is undergoing drastic changes. China is more competitive in commercial production with leading edges in many aspects," said GenScript Founder and CEO Zhang Fangliang.

Contact us at english@jschina.com.cn